Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...

Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares ...

Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Tuesday, setting a price target of $210, which is approximately 57.27 ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...

After hours: February 10 at 5:37:26 p.m. EST ...

Roche Holding AG Akt 1.04% CHF232.83B ...